ClinicalTrials.gg
CompletedNCT06348303Updated Aug 7, 2025

Study to Assess Drowsiness, Cognition, Fall Risk After Metaxalone 640 mg and Metaxalone 800 mg

A Phase 4 interventional study of Metaxalone m640 mg oral tablet and Metaxalone 800 mg oral tablet in Healthy Participants, sponsored by Primus Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-07.

Sponsored by Primus Pharmaceuticals · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Sep 2024, 2 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Every participant will receive Metaxalone in two (2) stages, one week after the other. A single dose of each Metaxalone dose will be taken one (1) time after a high fat meal which must be eaten within 30 minutes. Every participant will be given written tests to measure drowsiness, reaction time and thinking process and will also be asked to take walking tests to assess fall risk. Participation in this study will last approximately 2-4 weeks.

Read the detailed description

The Screening-Baseline Visit will include vital signs and urine testing, and a discussion of medications and current medical history. Participants will be given written tests to measure drowsiness, reaction time and thinking process and will also be asked to take walking tests to assess fall risk.

Visit 2 approximately one to two (1 to 2) week(s) later will be the first dosing day (Arm 1) after eating the high fat meal. The testing from Baseline will be repeated four (4) hours after the medication dose is taken.

Visit 3 approximately one (1) week later will be the second dosing day (Arm 2) after eating the high fat meal. The testing from Baseline will be repeated four (4) hours after the medication dose is taken.

The End of Study safety visit will take place one (1) week after Visit 3 by phone with a discussion of any side effects from the drug, recent medications, and any illness or injury experienced since the previous visit. Participants will be given end of study and discharge instructions.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Primus Pharmaceuticals is the lead sponsor of 21 studies on the registry; 4 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Weigh at least 120 pounds at Screening
  • Medically healthy with no medical co-morbidities impact endpoints

Exclusion criteria

Exclusion Criteria:

  • Current use of any medications known to affect sleep-wake cycle.
  • Known sleep disorder.
  • Current use of cimetidine.
  • Current use of a monoamine oxidase Inhibitor (MAOI), selective serotonin reuptake inhibitor (SSRI), selective norepinephrine reuptake inhibitor (SNRI), 5- hydroxytryptamine (5-HT) agonist or any drug that has the potential to affect the serotonergic neurotransmitter system (e.g. mirtazapine, trazodone, tramadol).
  • Positive urine test for amphetamines, barbiturates, cocaine, opiates, benzodiazepines, or cannabinoids.
  • Participants taking skeletal muscle relaxants or sedative hypnotics.
  • Participants with gastrointestinal disease affecting absorption.
  • Participants with severe hepatic or renal impairment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Active 640 mg

    Metaxalone (M640) 640 mg tablet, a single-dose at visit 2 of 4 visits.

    Drug: Metaxalone m640 mg oral tablet

  • Active comparator
    Active 800 mg

    Metaxalone 800 mg tablet, a single-dose at Visit 3 of 4 visits.

    Drug: Metaxalone 800 mg oral tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of participants unable to maintain Tandem Stand Position for more than 10 seconds (position 3 of the 4-Stage Balance Test).

    Validated 4-Stage Balance Test after completion of an FDA standardized high-fat meal. Place one foot in front of the other, heel touching toes.

    Time frame: Baseline, Visit 2 dosing (Day 1), Visit 3 dosing (Day 8)

  2. Change from baseline of gait during a stopwatch timed, stand, and walk activity from a seated position along a 30 foot path

    Timed Up and Go with Triaxial Accelerometry

    Time frame: Baseline, Visit 2 dosing (Day 1), Visit 3 dosing (Day 8)

  3. Change from baseline of correct number of steps taken on a fixed 4 inch wide, 9 feet long path

    Tandem Walk Test

    Time frame: Baseline, Visit 2 dosing (Day 1), Visit 3 dosing (Day 8)

Secondary outcomes

  1. Change from baseline of participants' subjective report of drowsiness on a 10-point scale

    Karolinska Sleepiness Scale where 1 = extremely alert and 10 = extremely sleepy, can't keep awake

    Time frame: Baseline, Visit 2 dosing (Day 1), Visit 3 dosing (Day 8)

  2. Change from baseline of reaction to stimulus by computer generated visual prompts measured in milliseconds

    Reaction Time Test (RTT)

    Time frame: Baseline, Visit 2 dosing (Day 1), Visit 3 dosing (Day 8)

  3. Change from baseline of participants' reasoning ability to recognize differences in six (6) computer generated shapes for 30 minutes

    Creyos Cognitive Test

    Time frame: Baseline, Visit 2 dosing (Day 1), Visit 3 dosing (Day 8)

  4. The number of product related adverse events experienced by participants from Visit 2 through Visit 4

    Adverse and Serious Adverse Events

    Time frame: Visit 2 dosing (Day 1, Visit 3 dosing (Day 8), Visit 4 End of Study (Day 15)

07

Study locations

1 site
  • ClinOhio Research Institute
    Columbus, Ohio 43213, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Sep 2024, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2024
First posted
Apr 4, 2024
StartActual
May 16, 2024
Primary completionActual
Sep 5, 2024
CompletionActual
Oct 30, 2024
Last update
Aug 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06348303
Lead sponsor
Primus Pharmaceuticals
Collaborators
ClinOhio Research Services, LLC
Responsible party
Sponsor
First posted
Apr 4, 2024
Start date
May 16, 2024
Primary completion
Sep 5, 2024
Completion
Oct 30, 2024
Last update
Aug 7, 2025

Study contacts

J Lukban, DO
study director · Primus Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metaxalone

Start the discussion